In 2024, on its 100th anniversary, the Novo Nordisk Foundation reached a new milestone, awarding close to DKK 10.1 billion (€1.35 billion) to support nearly 1,800 new projects aimed at improving people's health and the sustainability of society and the planet.
Novo Nordisk to cap insulin prices in Minnesota settlement
Bosses from Fortune 500 Europe companies including Novo Nordisk, Lego, and Carlsberg met with the PM as Trump ups his threats over Greenland.
Luckily, the hiring process proceeded smoothly and Charles van Zyl joined as chief executive from Belgian pharma company UCB (BE:UCB) in 2023, while Joerg Hornstein has been in post as chief finance officer since August 2022.
Denmark’s Novo Nordisk saw its shares rise as much as 13% to 659.20 kroner this morning, after it announced top-line results from a Phase Ib/IIa clinical trial with amycretin once weekly subcutaneous (SC) administration.
The Atlantic on MSN9d
Trump Triggers a Crisis in Denmark—And Europe"Trump might forget about Greenland. But also, he might not. Nobody knows. He operates on whims," @anneapplebaum writes.
Amycretin could give Novo a buzzy product in a newly competitive obesity market. It works similarly to existing GLP-1 products by mimicking a hormone in the body that provides a satiated feeling, which curbs hunger, but adds a different hormone in the pancreas.
Stock prices for Novo Nordisk fell by about 3% at market open after the Biden administration selected its revolutionary drugs for mandatory price negotiations.
This issue is preventing our website from loading properly. Please review the following troubleshooting tips or contact us at [email protected]. By submitting your ...
On 11 November 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules").
He has also threatened Denmark with tariffs if it didn’t sell ... The U.S. is by far Novo Nordisk’s biggest as well as fastest-growing market, where it has marketed its GLP-1 drugs for weight ...
Novo Nordisk today announced topline results from a phase 1b/2a clinical trial with amycretin, a unimolecular GLP-1 and amylin receptor agonist intended for once weekly subcutaneous administration. The trial investigated the safety,
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback